Published in Women's Health Weekly, March 4th, 2004
"According to a study from the United States, "The administration of 'consolidation' therapy is designed to maximize the benefits achieved from primary chemotherapy, to both improve progression-free and overall survival.
"Paclitaxel is an excellent agent to consider for a consolidation strategy in ovarian cancer, based on its activity in the disease, its cycle-specificity, and the lack of serious cumulative toxicity (except for neuropathy)," wrote M. Markman and colleagues, Cleveland Clinic Foundation, Department of Hematology and Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly